Cabotegravir demonstrated efficacy as a long-acting PrEP, with no new HIV cases in the PILLAR trial over 12 months. The combination of cabotegravir and rilpivirine showed high viral suppression rates ...
Long-acting CAB+RPV is preferred by patients for ART due to reduced dosing frequency and stigma, with 89% switching after viral suppression. Studies like PILLAR and EBONI confirm the effectiveness and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback